In this editorial, Rupert Payne, Consultant Editor for Prescriber, discusses the difference in pharmaceutical advertising regulations between the USA and UK.
Articles: 30.09 September 2019
Despite the availability of numerous treatments, glaucoma is still one of the leading causes of blindness in the UK. This article examines some of the factors that might be responsible, including poor compliance with eye drops and pressure on ophthalmology services, and discusses how these problems might be overcome
A systematic approach to evaluation and investigation is key to the successful management of anaemia. This article examines the classification of anaemia, its underlying causes and clinical manifestations, and the range of treatments available.
In 2018, the High Court ruled that CCGs can prescribe bevacizumab (Avastin) off-label for wet age-related macular degeneration (wet AMD). This article discusses the background to the case and its wider implications for drug licensing and clinical practice
In 2018, the Yellow Card Scheme reported a decline in the number of reported suspected adverse drug reactions, particularly among doctors and pharmacists. This article discusses the possible reasons for this and the action the MHRA is taking to improve reporting rates
There is now a wide range of monoclonal antibody therapies to choose from for the treatment of severe plaque psoriasis. This article examines their mechanisms of action, place in therapy, efficacy and safety
Andexanet alfa (Ondexxya) is the first licensed antidote to the direct factor Xa inhibitors apixaban or rivaroxaban, for use when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. This article summarises its indications, efficacy and safety.
Read the full article.